CLINICAL PROOF OF PRINCIPLE AND FAVORABLE TOLERABILITY PROFILE SHOWN WITH ORALLY DOSED MORF-057 AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE UC: PHASE 2A EMERALD-1 STUDY RESULTS

Bruce E. Sands  1     Stefan Schreiber  2     Silvio Danese  3     Jaroslaw Kierkus  4     Brihad Abhyankar  5     Michael Choi  5     Carolyn Soo  5     Yujun Wu  5     Fangui Sun  5     Dooyoung Lee  5     Dan Cui  5     Cuyue Tang  5     Maloy Mangada  5     Ali Hussain  5     Peter Linde  6     Adrian Ray  6     Oladele Babalola  5     Sharon Brown  5     Sarah Hammer  5     Kerry McConie  5     Bruce Rogers  5     Laurent Peyrin-Biroulet  7     Brian G. Feagan  8    
1 Icahn School of Medicine at Mount Sinai, New York, United States
2 University Hospital Schleswig-Holstein, Kiel, Germany
3 Vita-Salute San Raffaele University - IRCCS San Raffaele Scientific Institute, Milan, Italy
4 Children’s Memorial Health Institute, Warsaw, Poland
5 Morphic Therapeutic, Waltham, United States
6 Past Employee of Morphic Therapeutic, Waltham, United States
7 Inserm U1256, Nancy University Hospital, Vandoeuvre-les-Nancy, France
8 The University of Western Ontario, London, Canada

Topic
IBD

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing